$HEM declared the addition of an entirely closely-held subsidiar
Hemostemix recently declared the incorporation of PreCerv inc . (A totally closely-held subsidiary of Hemostemix). Hemostemix can grant PreCerv a world field of use licence for NCP-01 and its autologous somatic cell technology to treat central and peripheral systema nervosum diseases.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.